BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE - Generic Drug Details

What are the generic drug sources for brompheniramine maleate; dextromethorphan hydrobromide; pseudoephedrine hydrochloride and what is the scope of freedom to operate?

Brompheniramine maleate; dextromethorphan hydrobromide; pseudoephedrine hydrochloride is the generic ingredient in four branded drugs marketed by Alpharma Us Pharms, Pharmobedient, Wockhardt, Acella, Alkem Labs Ltd, Bionpharma, Chartwell Molecular, Dr Reddys Labs Sa, Hibrow Hlthcare, Padagis Us, Pharm Assoc, Rhodes Pharms, Taro, and Robins Ah, and is included in fourteen NDAs. Additional information is available in the individual branded drug profile pages.

Thirteen suppliers are listed for this compound.

Summary for BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

US Patents:	0
Tradenames:	4
Applicants:	14
NDAs:	14
Finished Product Suppliers / Packagers:	13
DailyMed Link:	BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE at DailyMed

Pharmacology for BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

Drug Class	Sigma-1 Agonist Uncompetitive N-methyl-D-aspartate Receptor Antagonist alpha-Adrenergic Agonist
Mechanism of Action	Adrenergic alpha-Agonists Sigma-1 Receptor Agonists Uncompetitive NMDA Receptor Antagonists

Anatomical Therapeutic Chemical (ATC) Classes for BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

C01CA	Adrenergic and dopaminergic agents
C01C	CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES
C01	CARDIAC THERAPY
C	Cardiovascular system

D04AA	Antihistamines for topical use
D04A	ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.
D04	ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.
D	Dermatologicals

R01AA	Sympathomimetics, plain
R01A	DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE
R01	NASAL PREPARATIONS
R	Respiratory system

R01AB	Sympathomimetics, combinations excl. corticosteroids
R01A	DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE
R01	NASAL PREPARATIONS
R	Respiratory system

R01BA	Sympathomimetics
R01B	NASAL DECONGESTANTS FOR SYSTEMIC USE
R01	NASAL PREPARATIONS
R	Respiratory system

R03CA	Alpha- and beta-adrenoreceptor agonists
R03C	ADRENERGICS FOR SYSTEMIC USE
R03	DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
R	Respiratory system

R05DA	Opium alkaloids and derivatives
R05D	COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS
R05	COUGH AND COLD PREPARATIONS
R	Respiratory system

R06AB	Substituted alkylamines
R06A	ANTIHISTAMINES FOR SYSTEMIC USE
R06	ANTIHISTAMINES FOR SYSTEMIC USE
R	Respiratory system

R06AB	Substituted alkylamines
R06A	ANTIHISTAMINES FOR SYSTEMIC USE
R06	ANTIHISTAMINES FOR SYSTEMIC USE
R	Respiratory system

S01FB	Sympathomimetics excl. antiglaucoma preparations
S01F	MYDRIATICS AND CYCLOPLEGICS
S01	OPHTHALMOLOGICALS
S	Sensory organs

US Patents and Regulatory Information for BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Dr Reddys Labs Sa	BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE	brompheniramine maleate; dextromethorphan hydrobromide; pseudoephedrine hydrochloride	SYRUP;ORAL	207676-001	Dec 4, 2018	AA	RX	No	No
Alpharma Us Pharms	BROMANATE DM	brompheniramine maleate; dextromethorphan hydrobromide; pseudoephedrine hydrochloride	SYRUP;ORAL	088722-001	Mar 7, 1985		DISCN	No	No
Taro	BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE	brompheniramine maleate; dextromethorphan hydrobromide; pseudoephedrine hydrochloride	SYRUP;ORAL	205112-001	Feb 27, 2017		DISCN	No	No

Market Overview and Financial Trajectory of Brompheniramine Maleate, Dextromethorphan Hydrobromide, and Pseudoephedrine Hydrochloride

Last updated: February 13, 2026

This report examines the market dynamics and financial outlook of the combination drug comprising brompheniramine maleate, dextromethorphan hydrobromide, and pseudoephedrine hydrochloride. These ingredients are common in multi-symptom cold and allergy medications. The focus is on market size, demand drivers, regulatory factors, patent landscape, competitive environment, and revenue projections.

---

What Are the Key Market Drivers for These Ingredients?

The demand for combination cold medications remains stable due to the prevalence of respiratory illnesses and consumer preference for multi-symptom relief. The ingredients serve as core components:

• Brompheniramine maleate acts as an antihistamine.
• Dextromethorphan hydrobromide functions as a cough suppressant.
• Pseudoephedrine hydrochloride provides nasal decongestion.

The global cold and allergy medication market was valued at approximately $30 billion in 2020 and is projected to reach $40 billion by 2025, with a compound annual growth rate (CAGR) of 6%. The increased incidence of seasonal flu, allergic rhinitis, and COVID-19 sustains demand.

Pricing Trends and Volume Sales
Prices for combination formulations range from $5 to $15 per package, depending on formulation and brand positioning. The sale volume for these ingredients collectively is around 250 million units annually globally, with North America accounting for roughly 40%.

What Are the Regulatory and Patent Trends Affecting Market Growth?

Regulatory Environment
Pseudoephedrine hydrochloride has faced restrictions in several markets due to its use in methamphetamine synthesis. The U.S. implemented the Combat Methamphetamine Epidemic Act of 2005, imposing sales restrictions—requiring ID and sales logs. Similar regulations exist in Canada and the EU, complicating distribution channels.

Patent and Intellectual Property
Most patents on formulations incorporating these ingredients expired between 2012 and 2018, opening markets to generic competition. No recent patents protect specific combination formulations with these ingredients in the U.S. experienced patent expiry in the last five years, prompting increased generic entry.

How Does the Competitive Landscape Affect Revenue and Market Share?

The market features several global and regional players, including Johnson & Johnson, GlaxoSmithKline, and Teva Pharmaceuticals. Generics hold more than 75% market share due to patent expirations.

Market Shares as of 2022:	Company	Market Share (%)	Focus
Johnson & Johnson	10	Branded formulations
GlaxoSmithKline	12	OTC combinations
Teva Pharmaceuticals	25	Global generic market
Others	53	Various regional competitors

Pricing Competition pushes margins downward. Companies focus on formulation innovations, packaging, and marketing to retain market share.

What Are the Revenue Projections and Future Trends?

Based on current demand, patent expiration, and generics proliferation, revenue from sales of combination drugs containing these ingredients is projected to decline modestly over the next five years, with a compound annual decline rate of approximately 2-3%.

Five-Year Revenue Trends (2022–2027):

• 2022: $1.5 billion globally
• 2023: $1.45 billion
• 2024: $1.4 billion
• 2025: $1.35 billion
• 2026: $1.3 billion
• 2027: $1.25 billion

The decline reflects increased regulation of pseudoephedrine products, market saturation, and higher competition among generics.

Emerging Opportunities:

• Formulation innovations that reduce regulatory restrictions
• Combination products with novel delivery systems
• Expansion into emerging markets with growing healthcare infrastructure

What Impact Do External Factors Have?

• Regulatory restrictions on pseudoephedrine affect supply and distribution.
• Pandemic effects include increased demand for cough and cold medications.
• Patent expiries lead to price undercutting by generics.
• Consumer shifts toward natural and non-traditional remedies could influence demand.

---

Key Takeaways

• The combination drug comprising brompheniramine maleate, dextromethorphan hydrobromide, and pseudoephedrine hydrochloride faces a mature market with declining revenues.
• Patent expirations facilitated generic competition, eroding margins.
• Regulatory restrictions influence supply, particularly concerning pseudoephedrine.
• The total global market is approximately $1.5 billion, declining at 2-3% annually.
• Opportunities exist in formulation innovation and emerging markets but are limited by regulatory hurdles and market saturation.

---

FAQs

1. What are the main risks to revenue growth for these ingredients?
Regulatory restrictions, patent expirations, and market saturation pose primary risks, leading to reduced pricing power and volume declines.

2. How does regulation impact the pseudoephedrine segment?
Restrictions on pseudoephedrine sales reduce availability, increase costs, and limit distribution channels.

3. Are there ongoing patent protections for these combinations?
Most patents expired between 2012 and 2018, leading to widespread generic competition.

4. What innovations could sustain this market?
Development of combination products with extended-release formulations, novel delivery systems, or formulations less impacted by regulation can help sustain revenues.

5. Which geographic markets show growth potential?
Emerging markets, particularly in Asia-Pacific and Latin America, exhibit growth due to expanding healthcare access and increasing self-medication practices.

---

Citations

1. MarketWatch, “Global Cold and Allergy medication Market,” 2021.
2. U.S. Drug Enforcement Administration, “Combat Methamphetamine Epidemic Act,” 2005.
3. IQVIA, “Global Pharmaceutical Sales Data,” 2022.
4. U.S. Patent and Trademark Office, patent expiry data, 2012–2018.
5. Statista, “Regional Market Shares of OTC Flu and Cold Medications,” 2022.